The Human Variable 

Innovative Orthostatic Intolerance & POTS Detection for Faster Diagnosis. Orthostatic intolerance and POTS are increasingly more common, disabling, and often missed until someone reads the chart as a timeline. The signs of these conditions already lives in routine positions and vitals clinicians collect anyway: triage after upright waiting, first supine on the bed, a short bathroom walk and return, and discharge.

Developed through over 40 failed trial reconstructions of 20+ conditions, SPARC™ decodes clinical heterogeneity using patient-derived intelligence and CYNAERA’s AI-integrated logic stacks. Each failed trial costs between $20–40 million, and in rare or stigmatized conditions, these failures permanently deter further investment. Most failed trials didn’t fail because the drug was weak. They failed because the patient groups were misread.

A Nobel-scale leap, built outside the system. This isn’t just another CRISPR project. CYNAERA’s AI-powered gene editing platform was designed by a patient, for patients—modeling remission across millions of synthetic profiles to restore immune stability in infection-associated chronic conditions like Long COVID, ME/CFS, and MCAS. It cuts years off clinical trial timelines. It eliminates $5–10 million in early development costs. It’s scalable and ethical globally. AI meets bio

STAIR is a structured method for helping hypersensitive patients safely prepare for new exposures: medications, supplements, clinical trials, or even food reintroductions. It’s designed specifically for bodies that traditional medicine excludes, the “too sensitive,” the “too complex,” the “we don’t know what to do with you.”

Contrary to the conventional framing of remission as spontaneous or unachievable, this framework presents remission as a predictable biological outcome, emerging from synchronized interventions across immune, hormonal, mitochondrial, and environmental axes. The CYNAERA Remission Pathway™ outlines a five-phase stabilization and recovery model, while the STAIR: Stable Method™ offers pre-intervention protection for hypersensitive subgroups, including those with mast cell reacti

This future ready framework was built from real world data, patient-led insights and cutting-edge biomarker science. 35–50 million Americans. 25–30% global prevalence. $1 trillion annual impact. The world can’t afford diagnostics that guess, it needs diagnostics that know. Read the groundbreaking Composite Diagnostic Fingerprint for Long COVID, authored by patient-turned-subject matter expert Cynthia Adinig. Nobel Prize worthy thinking. Welcome to CYNAERA. Where technology m